A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
This research is looking at a new medicine called LY4213663 for people with rheumatoid arthritis (RA). The main aim is to find out how safe it is and what side effects it might have in both healthy people and those with RA. Scientists also want to understand how the body uses and processes this new medicine. The medicine will be given either as a shot under the skin or through a drip into a vein. Participants will have blood tests to see how the medicine acts in their bodies. The study will last about 33 weeks, not including the first check-up period. It's a 'Phase 1' study, which means it's one of the first times this medicine is being tested in people.
במבט חטוף
על מה המחקר הזה?
This study is about a new medicine called LY4213663, which is being developed to treat rheumatoid arthritis (RA). RA is a condition where your body's immune system mistakenly attacks your own healthy tissues, causing pain, swelling, and stiffness in your joints. Finding new and better treatments is very important for people living with RA.
The main goal of this study is to learn more about this new medicine. Specifically, researchers want to see if it's safe to use, what side effects people might experience, and how the body handles the medicine. They also want to understand how the medicine affects the body once it's taken. By carefully studying healthy volunteers first, and then people with RA, scientists can gather important information in a safe and step-by-step way.
Understanding how a new medicine works and ensuring it's safe is the first important step before it can be made widely available. This 'Phase 1' study is crucial for gathering this early information and helping decide if the medicine should be studied further in larger groups of people. Every new treatment starts with studies like this one, carefully checking for safety and how the medicine behaves in the body.
נקודות עיקריות
- This study is testing a new medicine (LY4213663) for rheumatoid arthritis.
- It aims to find out if the medicine is safe and what side effects it might cause.
- Both healthy people and those with rheumatoid arthritis can take part.
- The medicine will be given either as a shot or through a drip.
- The study involves blood tests and lasts about 33 weeks.
- בריאותך תיבדק בקפידה לאורך כל המחקר.
מי עשוי להיות זכאי?
To join this study, you'd generally need to be between 18 and 75 years old. Your body mass index (BMI), which is a measure of your weight compared to your height, needs to be within a certain range.
If you have rheumatoid arthritis, you must have been diagnosed with it for at least three months. It's also important that your RA isn't too severe (not 'Class 4' according to a standard medical classification). You should not have any current or recent serious infections, and your heart health will be checked.
If you are a healthy person interested in taking part, you should not have any major long-term health problems with your heart, lungs, liver, kidneys, or other major body systems that could affect how the medicine works in your body.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בין גיל 18 ל-75?
- Is your weight for your height (BMI) within a healthy range?
- If you have RA, have you been diagnosed for at least 3 months?
- Do you currently have any serious active infections?
- Do you have any major heart problems?
- Do you have severe rheumatoid arthritis (Class 4)?
מה כרוך בהשתתפות?
If you decide to take part, you'll first have a screening visit to check if the study is right for you. If you qualify, you will receive the study medicine, LY4213663, either as a small injection under your skin or through a drip directly into a vein in your arm. Some participants might receive a placebo, which looks like the study medicine but contains no active ingredient. This helps researchers compare the effects of the real medicine.
You'll have regular blood tests to help the study team understand how the medicine is working in your body and how your body is responding to it. You will also have check-ups to monitor your health and look for any side effects. The total time you'll be involved in the study, not including the initial screening, will be around 33 weeks.
סיכונים ותועלות פוטנציאליים
מיקומים (10)
- Pinnacle Research Group, LLCמיקוד מאומתAnniston, United States· גיוס
- Arizona Research Centerמיקוד מאומתפניקס, ארצות הברית· גיוס
- Clinical Research of West Florida, Inc. (Clearwater)מיקוד מאומתClearwater, United States· גיוס
- GNP Research at Mark Jaffe, MDמיקוד מאומתCooper City, United States· גיוס
- Fortrea Clinical Research Unitמיקוד מאומתדייטונה ביץ', ארצות הברית· גיוס
- AGA Clinical Trialsמיקוד מאומתהיאליה, ארצות הברית· גיוס
- Advanced Pharma CR, LLCמיקוד מאומתמיאמי, ארצות הברית· גיוס
- מחקר קליני פלורידיאנימיקוד מאומתמיאמי לייקס, ארצות הברית· גיוס
- Oasis Clinical Researchמיקוד מאומתLas Vegas, United States· גיוס
- Universitätsklinikum Charitéמיקוד מאומתברלין, גרמניה· עדיין לא מגייסים
שאלות נפוצות
What is rheumatoid arthritis?
Rheumatoid arthritis (RA) is a condition where your body's immune system attacks your joints, causing pain, swelling, and stiffness.
What does 'Phase 1' mean?
Phase 1 means this is one of the first times the new medicine is being tested in people to check its safety and how it works in the body.
מהו פלצבו?
A placebo looks just like the study medicine but doesn't contain any active drug. It helps researchers compare the effects of the real medicine.
כיצד יינתן התרופה?
The medicine will be given either as an injection under the skin (subcutaneously) or through a drip into a vein (intravenously).
כמה זמן יימשך המחקר?
The study will last about 33 weeks, not including the initial check-up period.
כיצד לגלות עוד
שאלות לגבי הניסוי או שאלות השתתפות: 1-877-CTLILLY (1-877-285-4559) או
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.